AI summary · may contain errors
Temporary interruption of adjuvant endocrine therapy for pregnancy in HR-positive early breast cancer patients (≤42 years) is linked to 5-year BCFI event incidence of 12.3% in POSITIVE.
- 1 cited this week
- Open access
Moving in Annals of Oncology and Cancer Cell.
Rebuilt
AI summary · may contain errors
Temporary interruption of adjuvant endocrine therapy for pregnancy in HR-positive early breast cancer patients (≤42 years) is linked to 5-year BCFI event incidence of 12.3% in POSITIVE.
AI summary · may contain errors
CPS + EG and Neo-Bioscore scores are linked to long-term outcomes at the patient level, but they do not predict long-term outcomes at the trial level in neoadjuvant therapy studies.
Newest first · last 60 days
AI summary · may contain errors
FlahyRecovery subtypes tumor microenvironments into Hot, Cold, and Intermediate using 1275 immune signaling genes, achieving 79% sensitivity, 89% specificity, and one-vs-rest AUC 0.93 in N=1337.
AI summary · may contain errors
Updated findings from the IDEA nonrandomized clinical trial report on treatment options for postmenopausal patients with estrogen receptor–positive breast cancer after radiotherapy omission in younger patients.
AI summary · may contain errors
SpacePhenotyper transfers bulk gene-expression predictors of patient-level clinical phenotypes to spatial transcriptomics, enabling spot-level quantification of residual cancer burden in breast tumors.
AI summary · may contain errors
Negative lumpectomy margins under 2 mm in ductal carcinoma in situ are not linked to higher ipsilateral recurrence risk in 11,156 women overall, except for age <50 years.
AI summary · may contain errors
A 16-fraction hypofractionated postmastectomy radiation regimen (42.56 Gy) is noninferior to conventional PMRT (50 Gy) for reconstruction complications in women undergoing breast reconstruction.
AI summary · may contain errors
Advanced platinum approaches for triple-negative breast cancer are being expanded beyond standard cytotoxicity, leveraging Pt(IV) prodrugs, targeted complexes, and tumor-responsive delivery to address resistance and toxicity.
AI summary · may contain errors
Higher RHBDL2 expression is associated with chemoresistance and poor prognosis in patients with triple-negative breast cancer (TNBC), and RHBDL2 knockdown suppresses stemness and resistance in TNBC cells.
AI summary · may contain errors
In the PALLAS phase III trial for stage II–III hormone receptor-positive breast cancer, developing high-grade neutropenia (grade ≥3) on palbociclib plus endocrine therapy is linked to better 5-year invasive disease-free survival than endocrine therapy alone.
AI summary · may contain errors
Trastuzumab deruxtecan plus pertuzumab in ERBB2-positive metastatic breast cancer is linked to superior progression-free survival in DESTINY-Breast09, supporting FDA approval and reshaping first-line sequencing questions.
AI summary · may contain errors
Retriever identifies QL-XII-47 plus GSK-690693 as the topmost promising drug combination for antagonizing triple-negative breast cancer (TNBC) cell line transcriptional signatures, after testing 11,325 combinations.
AI summary · may contain errors
Neoadjuvant therapy plus additional post-surgical adjuvant therapy (NAPAT) is projected to lower US breast-cancer mortality to 23.0/100,000 by 2030, versus No NAPAT.
AI summary · may contain errors
S-023-0996 (41a) is a tumor cell-selective dual EZH2-EGFR inhibitor that more efficiently suppresses TNBC tumor growth and metastasis in preclinical models than EZH2+EGFR drug combinations.
AI summary · may contain errors
A harmonized atlas of 7,612 bulk breast cancer transcriptomes from 22 datasets resolves malignant transcriptional states, including stem-like and neuroendocrine-differentiated subtypes.
AI summary · may contain errors
A 37-gene ColoTubIn signature predicts paclitaxel sensitivity in patient-derived colon cancer models, with low scores linked to increased drug responsiveness.
AI summary · may contain errors
Chemoresponsive triple-negative breast cancer PDX models show distinct transcriptional trajectories that diverge within one week of chemotherapy, with early cytokine and apoptotic pathway activation absent in chemoresistant models.
AI summary · may contain errors
Glycoprotein nonmetastatic melanoma protein B overexpression is strongly upregulated in CDK4/6 inhibitor–resistant estrogen receptor-positive breast cancer models and predicts failure of CDK4/6 blockade.
AI summary · may contain errors
Temporal ordering of spatial transcriptomes from 100+ ducts in triple-negative breast cancer mice maps spatiotemporal tumor microenvironment remodeling and identifies early stromal programs and signaling axes.
AI summary · may contain errors
WCRC-25, an invasive lobular carcinoma cell line from a patient pleural effusion, shows luminal Her2-like features and confirmed PI3K/AKT inhibitor sensitivity.
AI summary · may contain errors
Disease-free survival and distant metastasis-free survival are strong surrogate endpoints for disease-specific survival in resected melanoma, with R2 up to 0.95 at 24–36 months.
AI summary · may contain errors
Risk-adapted de-escalation of neoadjuvant therapy in stage II–III HER2-positive early-stage breast cancer is supported by trials showing carboplatin omission is feasible for most patients.
AI summary · may contain errors
Intratumoral androstenedione (A4) levels in breast cancer specimens are linked to a 90-gene transcriptional classifier that stratifies patients into low, intermediate, and high A4 groups with different outcomes.
AI summary · may contain errors
In 25 ER-positive breast cancer patients, single-cell profiling links high ER signaling and ER-bound enhancer activity to sensitivity to neoadjuvant aromatase inhibitors.
AI summary · may contain errors
Iza-bren (BL-B01D1) showed clinically meaningful antitumor activity in heavily pretreated metastatic breast cancer, with confirmed objective response rates of 46.3% in HER2-positive patients.
Journals this month
Topics moving, week to 17 Nov 2026
By field